Sofibac Competitors

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities, to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. With approximately 7,000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Baar, Switzerland and we have world-class manufacturing facilities in North Carolina and Solothurn, Switzerland. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. For more information, please visit www.biogen.com. Community Guidelines: https://www.biogen.com/community-guidelines.html Follow us on social media – LinkedIn, Instagram, Facebook, X, and YouTube.

With deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs.

PureTerra Ventures is a specialist venture capital firm focused on investing in disruptive water technologies with great financial returns and a positive social impact. We look for water companies that are ready to scale commercially to invest between 1-5M euros for a first ticket. We have a global investment scope with our head office in Amsterdam, The Netherlands. Our fund combines strong entrepreneurial experience, a proven track record in driving sales and a vast network in the global water technology market to create a unique value proposition for our investors and portfolio companies alike. PureTerra Ventures has access to the largest network of distributors, utilities, government departments, blue chip companies and other key players in the Chinese water market. We leverage this network to actively contribute to the commercial success of our portfolio companies. We are not just as a financial investor, but a strategic partner in the global water market.